Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
1 finding from 1 review
Patient‐reported pain intensity or pain relief: VAS (1 mm to 100 mm) ‐ 24 hours. Assumed risk: Not measured. Corresponding risk: not estimable. 39 participants (1 RCT). Quality: very low. Comments: insufficient…
1 study · 39 participants
Very low
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adolescents and adults undergoing orthodontic treatment
Vibratory stimulation (vibratory adjuncts) showed no clear difference in patient‐reported pain intensity or pain relief (VAS, NRS or… compared with no vibration or placebo vibration; GRADE not reported.
5 findings from 1 review
MD 1.28 [-3.16, 5.71]
3 studies · 154 participants
GRADE not reported
MD -0.52 [-9.41, 8.36]
2 studies · 115 participants
GRADE not reported
Lobre 2015 (high risk of bias): mean overall pain intensity 8.49 mm lower on the VAS during the second month (P = 0.04) and 6.26 mm lower during the fourth month (P = 0.03); no evidence of benefit at month one or month…
2 studies
GRADE not reported
Show 2 more findings
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adults undergoing orthodontic treatment
Brain wave music (BWM) showed no clear difference in patient‐reported pain intensity or pain relief (VAS, NRS or… compared with no special instructions (control); GRADE not reported.
3 findings from 1 review
MD -4.72 [-15.83, 6.39]
1 study · 24 participants
GRADE not reported
MD -26.65 [-39.06, -14.24]
1 study · 24 participants
Very low
MD -23.44 [-36.82, -10.06]
1 study · 24 participants
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether cholinergics (bethanechol 15 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether psychological therapies (cognitive therapy) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
2 findings from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · capsaicin oral rinse
Capsaicin oral rinse (Marino 2010; Silvestre 2012) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory). Silvestre 2012 data not presented due to 23% first-phase…
1 study
GRADE not reported
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomeslong-term (>3 to 6 months) · capsaicin oral rinse
MD -2.60 [-5.11, -0.09]
1 study · 18 participants
Very low
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Dose/intensity and frequency of pain relief needed (analgesic/rescue medication use) · Adolescents and adults undergoing orthodontic treatment
Vibratory stimulation (vibratory adjuncts) led to lower dose/intensity and frequency of pain relief needed (analgesic/rescue… compared with no vibration or placebo vibration; GRADE not reported.
1 finding from 1 review
RR 0.63 [0.44, 0.92]
2 studies
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · Catuama
'Catuama' herbal compound (Spanemberg 2012) contributes to the dietary supplements short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
1 study · 72 participants
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector + reinforced self-control… changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · lycopene
Lycopene (Cano-Carrillo 2014) contributes to the dietary supplements short-term symptom-relief comparison (12 RCTs, insufficient/contradictory); no separate lycopene symptom-relief estimate reported.
1 study · 50 participants
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · topical urea 10%
Topical urea 10% (Alvarenga da Silva 2014) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
1 study · 38 participants
GRADE not reported
Adverse events: hypertension · patients with Guillain‐Barré syndrome
Corticosteroid leads to lower adverse events ‐ hypertension compared with control (high certainty).
1 finding from 1 review